Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-09-14

Intellia Therapeutics, Inc.

Intellia Therapeutics develops in vivo CRISPR gene-editing therapies for hereditary angioedema, transthyretin amyloidosis and other severe diseases.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

First Approval Could Reframe the Platform

A clean lonvo-z approval and launch could move the company from partner-funded science to owned rare-disease economics. The upside is meaningful, but the market still needs proof that irreversible editing can scale through regulators, payers and physicians.

Analysis

Thesis

NTLA can rerate from a collaboration-funded gene-editing platform into a commercial rare-disease company if lonvo-z converts Priority Review into a clean 2027 launch, while nex-z and selective licensing add second and third revenue streams by 2031.

Last Economy Alignment

AI helps Intellia design, interpret and compound human editing data faster, but value still depends on regulated trust, safety and execution rather than software scale alone.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.7x (from 5 most recent analyses)

Reasoning

The upside case is a business-model transition rather than a pure science bet. If lonvo-z proves regulators, payers and treatment centers will support one-time editing, Intellia can shift from lumpy collaboration revenue to owned product revenue, then add ATTR economics and selective licensing. That mix can justify a durable premium to a pre-commercial biotech, but the path is still too gated for a central 5-10x equity case.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The setup is attractive because one approval can change the business model quickly, but the path is narrow. The biggest risks are a disappointing lonvo-z review or launch, slower-than-expected adoption of irreversible editing, and failure of nex-z to convert its safety learnings into a credible ATTR franchise.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

FDA accepted lonvo-z's BLA on September 8, 2026 and set a March 10, 2027 PDUFA date, moving the story from filing risk to review risk.
The September 4, 2026 OrbiMed facility added $75 million upfront and created access to milestone-based debt tranches, easing immediate dilution pressure.
No new public confirmation has yet closed the nex-z enrollment gate, so the second major value driver still needs fresh operational proof.

Thesis update

Not fundamental. The core thesis is intact, but the first major regulatory step is now clearer and slightly more financeable.

Forecast update

No major framework change. Recent updates mainly remove part of the near-term uncertainty discount rather than changing the long-run opportunity set.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.37

They do not sell software that AI can copy overnight; they own clinical data, regulatory files and a potential one-time treatment workflow. AI helps them learn faster, but biology, safety and the FDA still control the clock.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$23.94

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research